Fredun Pharmaceuticals' Q2 FY 2026-27 Quarterly Results
- 06 Nov 2026
Result Summary
- Fredun Pharmaceuticals Ltd reported a 17.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 84.2%.
- Its expenses for the quarter were up by 14.6% QoQ and 79.5% YoY.
- The net profit increased 41.4% QoQ and increased 96.9% YoY.
- The earnings per share (EPS) of Fredun Pharmaceuticals Ltd stood at 10.92 during Q2 FY 2026-27.
Financial Statments for Q2 FY 2026-27
(₹ crores) | Q2FY27 | Q1FY27 | Q2FY26 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 267.64 | 228.25 | 145.29 | 17.3% | 84.2% |
Total Expenses | 237.99 | 207.70 | 132.58 | 14.6% | 79.5% |
Profit Before Tax | 29.65 | 20.55 | 12.71 | 44.3% | 133.3% |
Tax | 11.08 | 7.42 | 3.27 | 49.3% | 238.8% |
Profit After Tax | 18.57 | 13.13 | 9.43 | 41.4% | 96.9% |
Earnings Per Share | 10.92 | 22.19 | 19.98 | -50.8% | -45.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Fredun Pharmaceuticals Ltd is a pharmaceutical company operating within the healthcare and life sciences industry. The company is primarily engaged in the research, development, manufacturing, and distribution of pharmaceutical products. Fredun Pharmaceuticals focuses on providing a wide range of therapeutic solutions, catering to various healthcare needs. Key areas of their portfolio potentially include generic medicines, specialty drugs, and active pharmaceutical ingredients (APIs). However, specific details about their product offerings are not available in the provided data. The company has been known to operate both in domestic and international markets, though recent developments or strategic initiatives have not been detailed in the available information.
Revenue
During the second quarter of the fiscal year 2027 (Q2FY27), Fredun Pharmaceuticals Ltd reported a total income of ₹267.64 crores, which marked a 17.3% increase from the previous quarter (Q1FY27) where the total income was ₹228.25 crores. When compared to the same quarter in the previous fiscal year (Q2FY26), there was a significant year-over-year growth of 84.2%, with total income previously recorded at ₹145.29 crores. This data indicates a robust upward trend in revenue generation over the last year. The increase in total income suggests effective strategies in sales or expansion in market reach during this period.
Profitability
The profitability of Fredun Pharmaceuticals Ltd has shown a considerable improvement in Q2FY27. The company reported a profit before tax of ₹29.65 crores, which is a 44.3% increase from the ₹20.55 crores reported in Q1FY27. Compared to the same quarter in the previous fiscal year (Q2FY26), where profit before tax was ₹12.71 crores, there was a substantial year-over-year growth of 133.3%. The tax expense for Q2FY27 was ₹11.08 crores, representing a 49.3% increase from Q1FY27 and a notable 238.8% increase year-over-year. Consequently, the profit after tax for Q2FY27 stood at ₹18.57 crores, reflecting a 41.4% increase quarter-over-quarter and a 96.9% increase year-over-year from Q2FY26. These figures highlight a period of enhanced profitability for the company.
Operating Metrics
Fredun Pharmaceuticals Ltd's operating metrics include the earnings per share (EPS), which for Q2FY27 was ₹10.92. This represents a significant quarter-over-quarter decline of 50.8% from the previous quarter's EPS of ₹22.19. Additionally, when compared to the same quarter in the previous fiscal year (Q2FY26), where the EPS was ₹19.98, there was a year-over-year decrease of 45.3%. The total expenses for Q2FY27 were ₹237.99 crores, showing a 14.6% increase from Q1FY27 and a 79.5% increase from Q2FY26. This data suggests variations in cost management or changes in operational scales that could have impacted these metrics.
FAQs
Fredun Pharmaceuticals Ltd announced its Q2 FY 2026-27 results on 6 November, 2026.
Fredun Pharmaceuticals Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Fredun Pharmaceuticals Ltd Q2 FY 2026-27 results include:
- Revenue: ₹267.64 crore
- Net Profit: ₹18.57 crore
- EBITDA: ₹42.36 crore
- Year-over-Year Growth: 84.2%
- Quarter-over-Quarter Growth: 17.3%
Fredun Pharmaceuticals Ltd reported a net profit of ₹18.57 crore in Q2 FY 2026-27, reflecting a 96.9% year-over-year growth.
Fredun Pharmaceuticals Ltd posted a revenue of ₹267.64 crore in Q2 FY 2026-27.